ArticleInvestigative ophthalmology & visual science2016
Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis.
Article in Investigative ophthalmology & visual science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 61 citations in OpenAlex.
- Harnessing inter-spheroid spacing and structural connectivity to direct collective cell migration and host vessel integration in 3D engineered tissue.Materials today. Bio · 2026Article
- Article
- Matrix Metalloproteinase 14 in Corneal Neovascularization.International journal of molecular sciences · 2026Review
- Selective Degradation and Inhibition of SARS-CoV-2 3CLInternational journal of molecular sciences · 2025Article
- Potential target within the tumor microenvironment - MT1-MMP.Frontiers in immunology · 2025Review
- Microenvironmental regulation of tumor-associated neutrophils in malignant glioma: from mechanism to therapy.Journal of neuroinflammation · 2024Review
- A novel tissue-engineered corneal epithelium based on ultra-thin amniotic membrane and mesenchymal stem cells.Scientific reports · 2024Article
- Available Therapeutic Options for Corneal Neovascularization: A Review.International journal of molecular sciences · 2024Review
- The amplitude of low frequency fluctuation and spontaneous brain activity alterations in age-related macular degeneration.Frontiers in medicine · 2024Article
- Fluorescence-Based Peptidolytic Assay for High-Throughput Screening of MMP14 Inhibitors.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Impact of Fibrinogen, Fibrin Thrombi, and Thrombin on Cancer Cell Extravasation Using In Vitro Microvascular Networks.Advanced healthcare materials · 2023Article
- Identification of small molecule inhibitors against MMP-14 via High-Throughput screening.Bioorganic & medicinal chemistry · 2023Article
- The Role of Membrane-Type 1 Matrix Metalloproteinase-Substrate Interactions in Pathogenesis.International journal of molecular sciences · 2023Review
- Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: development,Drug delivery · 2022Article
- Development of a naringenin microemulsion as a prospective ophthalmic delivery system for the treatment of corneal neovascularization:Drug delivery · 2022Article
- Transcriptomic Profiling of Human Limbus-Derived Stromal/Mesenchymal Stem Cells-Novel Mechanistic Insights into the Pathways Involved in Corneal Wound Healing.International journal of molecular sciences · 2022Article
- Effects of Tegafur, Gimeracil and Oteracil Potassium Capsules combined with Calf Spleen Extractive Injection on serum VEGF and MMP-9 in patients with advanced gastric cancer.American journal of translational research · 2022Article
- Proteolytic Cleavage of Receptor Tyrosine Kinases.Biomolecules · 2021Review
- Angioregulatory microRNAs in Colorectal Cancer.Cancers · 2019Review
- EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling.JCI insight · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purposeMatrix metalloproteinase 14 (MMP14) has been shown to be required for corneal angiogenesis. We hypothesized that the proangiogenic activity of MMP14 may be based on its selective binding to, and cleaving of, vascular endothelial growth factor receptor 1 (VEGFR1), but not VEGFR2 or VEGFR3.
methodsRecombinant human (rh)VEGFR1, R2, and R3 were incubated with human MMP14, and the reaction mixtures were analyzed by SDS-PAGE and Coomassie blue staining. Surface plasmon resonance was used to determine the equilibrium constants (KD) for binding between MMP14 and VEGFA versus rhVEGFR1, R2, and R3. Extracellular signal-regulated kinase (ERK) phosphorylation was assayed in vascular endothelial cells after incubation with VEGF and various concentrations of MMP14. Ex vivo aortic ring tube formation assays and VEGFA micropocket corneal neovascularization assays were performed using Flk1Cre/Flk1mCherry/MMP14lox and Flk1mCherry/MMP14lox control mice.
resultsMaxtrix metalloproteinase 14 increased VEGFA-induced ERK phosphorylation in a time- and concentration-dependent manner in vascular endothelial cells. Aortic ring assays showed diminished vessel sprouting in vitro in response to VEGFA, but not to basic fibroblast growth factor, in mice with conditional deletion of vascular MMP14 (Flk1creMMP14lox) compared with that in MMP14lox control mice. In addition, diminished VEGFA-induced corneal angiogenesis was seen in flk1creMMP14lox mice compared with MMP14lox mice in vivo.
conclusionsOur findings indicate that VEGFR1 interaction with MMP14 and the enzymatic activity of MMP14 are necessary for VEGFA-induced angiogenesis. Additionally, selective cleavage of VEGFR1 by MMP14 may play an important role in VEGFA-induced corneal angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.